

REMARKS

Claims 11-12, and 14-15 are currently pending. Claims 1-10, and 13 are cancelled without prejudice. Claim 11 is currently amended without prejudice. Applicants would like to thank the Examiner for indicating that claims 14 and 15 contain allowable subject matter. No new matter has been added.

Claim 11 has been amended to change its dependency to independent claim 14. Applicants submit that this amendment adds no new subject matter requiring a new search and/or further consideration by the Examiner.

No new matter has been added by these amendments.

Rejections under 35 U.S.C. § 103(a)

Following the Panel's Decision in the Notice of Panel Decision from Pre-Appeal Brief Review mailed February 22, 2006, claims 1-13 stand rejected under 35 U.S.C. § 103(a).¹ Claims 1-10, and 13 are herein cancelled without prejudice. Claim 11 has been amended to depend from independent claim 14 (indicated as allowable by the Examiner). Claim 12 depends from claim 11. Accordingly, Applicants respectfully submit that the rejections of claims 1-13 are moot.


CONCLUSION

It is believed claims 11-12, and 14-15 are in condition for allowance.

No fee is believed due for this response. Should any fee(s) be due at this time, please charge such fee(s) to Jones Day Deposit Account No. 503013.

Respectfully submitted,

Date: March 20, 2006


Brent P. Ray
For: Gidon D. Stern
(Reg. No. 27,469)

54,390
(Reg. No.)

JONES DAY
222 East 41st Street
New York, New York 10017
(212) 326-3939

¹ Specifically, claims 1 and 3-9 stand rejected under 35 U.S.C. § 103(a) as being unpatentable over United States Patent No. 5,019,075 to Spears *et al.* ("Spears") in combination with United States Patent No. 5,700,243 to Narciso, Jr. ("Narciso"), claim 2 stands rejected under 35 U.S.C. § 103(a) as being unpatentable over Spears in combination with Narciso, and further in view of United States Patent No. 5,445,608 to Chen *et al.* ("Chen"), claims 10-12 stand rejected under 35 U.S.C. § 103(a) as being unpatentable over U.S. Patent No. 5,041,109 to Abela ("Abela") in combination with U.S. Patent No. 6,547,787 to Altman *et al.* ("Altman"), and claim 13 stands rejected under 35 U.S.C. § 103(a) as being unpatentable over Abela in combination with Altman, and further in view of United States Patent No. 5,417,667 to Tennican *et al.* ("Tennican").